Critical Outcome Adds a Canadian Patent to COTI-2''s Growing Intellectual Property Portfolio
P53-Dependent Cancer Treatment IP Coverage Extended to Home Market
(firmenpresse) - LONDON, ONTARIO -- (Marketwired) -- 10/15/14 -- Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX VENTURE: COT)(OTCQB: COTQF), the bioinformatics and accelerated drug discovery company, announced today that its lead cancer drug candidate, COTI-2, has received its first Canadian patent, adding to a portfolio that includes six U.S. patents and one Japanese patent.
"This Canadian composition of matter patent follows on the heels of our recently announced sixth U.S. and first Japanese patent, further solidifying the intellectual property position surrounding our lead oncology asset," said Dr. Wayne Danter, President and CEO. "As we continue the development of COTI-2 towards a clinical trial, we are building a strong patent portfolio that will support and facilitate future commercial licensing opportunities."
Canadian Patent No. 2,673,683 covers the COTI-2 family of compounds, pharmaceutical preparations containing COTI-2, and methods of manufacturing the compounds. This subject matter has previously been covered in patents received in the U.S. and Japan.
About Critical Outcome Technologies Inc.
COTI is a leading-edge bioinformatics company specializing in accelerating the discovery and development of small molecules - dramatically reducing the time and cost to bring new drugs to market. COTI''s proprietary artificial intelligence system, CHEMSAS®, utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.
For more information, visit .
Follow (at)CriticalOutcome on Twitter at .
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Critical Outcome Technologies Inc.
Dr. Wayne Danter
President & CEO
519-858-5157
Heisler Communications
Trevor Heisler
Investor Relations
416-500-8061
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 15.10.2014 - 07:00 Uhr
Sprache: Deutsch
News-ID 1310028
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
LONDON, ONTARIO
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 148 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Critical Outcome Adds a Canadian Patent to COTI-2''s Growing Intellectual Property Portfolio
"
steht unter der journalistisch-redaktionellen Verantwortung von
Critical Outcome Technologies Inc. (COTI) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
